4Jaglowski SM, Linden E, Termuhlen AM, et al. Lymphoma in adolescents and young adults[J]. Semin Oncol, 2009,36(5):381-418. 被引量：1
5Erber E, Lira U, Maskarinec G, et al. Common immune-related risk factors and incident non-Hodgkin lymphoma: the multiethnic cohort[]]. Int J Cancer, 2009,125 (6) :1440-1445. 被引量：1
6Coleman M, Leonard J, Shuster MW, et al. DICE (dexamethasone, ffosfamide, cisplafin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL)[J]. Eur J Haematol Suppl, 2001, 64: 41-45. 被引量：1
7Olivieri A, Brunori M, Capelli D, et al, Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis [J]. EurJ Haematol, 2004, 72(1): 10-17. 被引量：1
8Oki Y, McLaughlin P, Pro B, et al. Phase Ⅱ study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma[J]. Cancer, 2005, 104(4): 781-787. 被引量：1
9Chan I, Harries M, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hoclgkin's lymphoma[]]. Br J Haematol, 2004, 120(6): 970-977. 被引量：1
10Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase Ⅱ study by the National Gancer Institute of Canada Clinical Trials Group (NGIC-CTG)[]]. Cancer, 2004, 101(8): 1835-1842. 被引量：1
